MedTrace Logo

Beovu Experience UZ Leuven

NCT05220085 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2022-02-02

No results posted yet for this study

Summary

Reporting early real-world clinical data of consecutive patients on the use of Beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution

Intravitreal injection

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Julie Jacob, MD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-11-01
Completion
2022-04-01
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05220085 on ClinicalTrials.gov